Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.

Manon de Vries-Brilland,Marine Gross-Goupil,Valérie Seegers,Elouen Boughalem,Benoit Beuselinck,Constance Thibault,Christine Chevreau,Sylvain Ladoire,Philippe Barthélémy,Sylvie Negrier,Delphine Borchiellini,Olivier Huillard,Lionnel Geoffrois,Gwenaelle Gravis,Carolina Saldana,Antoine Thiery-Vuillemin,Bernard Escudier,Alain Ravaud,Laurence Albiges

European Journal of Cancer（2020）

引用 22|浏览87

暂无评分

摘要

•Papillary renal cell carcinoma (pRCC) is the most common non-clear RCC.•We evaluated the efficacy of immune checkpoint inhibitors in metastatic pRCC.•Single agent PD-1 inhibitors exhibit limited activity in pretreated metastatic pRCC.•Prospective combinations clinical trials are needed in pRCC.

查看译文

关键词

Metastatic papillary renal cell cancer,Immunotherapy,PD-1/PD-L1 inhibitors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要